Marco Enea

3.7k total citations
70 papers, 2.1k citations indexed

About

Marco Enea is a scholar working on Hepatology, Epidemiology and Surgery. According to data from OpenAlex, Marco Enea has authored 70 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 37 papers in Hepatology, 33 papers in Epidemiology and 10 papers in Surgery. Recurrent topics in Marco Enea's work include Liver Disease Diagnosis and Treatment (28 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and Hepatitis C virus research (16 papers). Marco Enea is often cited by papers focused on Liver Disease Diagnosis and Treatment (28 papers), Hepatocellular Carcinoma Treatment and Prognosis (16 papers) and Hepatitis C virus research (16 papers). Marco Enea collaborates with scholars based in Italy, United Kingdom and Spain. Marco Enea's co-authors include Calogero Cammà, Antonio Craxı̀, Giuseppe Cabibbo, Massimo Attanasio, Florence Wong, Francesco Salerno, Martin Rössle, Jordi Bruix, Salvatore Petta and V. Di Marco and has published in prestigious journals such as SHILAP Revista de lepidopterología, Gastroenterology and Hepatology.

In The Last Decade

Marco Enea

66 papers receiving 2.0k citations

Peers

Countries citing papers authored by Marco Enea

Since Specialization

Citations

This map shows the geographic impact of Marco Enea's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marco Enea with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marco Enea more than expected).

Fields of papers citing papers by Marco Enea

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Marco Enea. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marco Enea. The network helps show where Marco Enea may publish in the future.

Co-authorship network of co-authors of Marco Enea

This figure shows the co-authorship network connecting the top 25 collaborators of Marco Enea. A scholar is included among the top collaborators of Marco Enea based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marco Enea. Marco Enea is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Evolution of Hospitalisation Due to Stroke in Italy Before and After the Outbreak of the COVID-19 Epidemic: A Population-Based Study Using Administrative Data 2025 ·Journal of Clinical Medicine ·Emanuele Amodio, (unknown), (unknown), (unknown), Vito M. R. Muggeo, Laura Maniscalco, Michela Conti, Maria Sergio, Antonio Cascio, Antonino Tuttolomondo, Domenica Matranga, Francesco Vitale, Marco Enea	0
2	Glucagon-like peptide-1 receptor agonist use is associated with a lower risk of major adverse liver-related outcomes: a meta-analysis of observational cohort studies 2025 ·Gut ·Ciro Celsa, Grazia Pennisi, (unknown), (unknown), (unknown), (unknown), (unknown), David J. Pinato, Giuseppe Cabibbo, Marco Enea, Alessandro Mantovani, Herbert Tilg, Giovanni Targher, Calogero Cammà, Salvatore Petta	7
3	Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma 2025 ·JAMA Oncology ·Ciro Celsa, (unknown), Pasquale Lombardi, Antonio D’Alessio, Claudia Angela Maria Fulgenzi, (unknown), Giulia Francesca Manfredi, Bernardo Stefanini, (unknown), Cristina Rigamonti, Mario Pirisi, (unknown), (unknown), Marco Enea, Calogero Cammà, Giuseppe Cabibbo, David J. Pinato	0
4	A Markov Model Unveiling the Impact of Resmetirom on the Natural History of MASLD Patients: A Sistematic Review and Meta‐Analysis 2025 ·Liver International ·Grazia Pennisi, (unknown), Marco Enea, (unknown), Ciro Celsa, (unknown), (unknown), (unknown), (unknown), Claudia La Mantia, (unknown), V. Di Marco, Calogero Cammà, Salvatore Petta	1
5	Early Hepatic Decompensation Identifies Patients with Hepatocellular Carcinoma Treated with Atezolizumab plus Bevacizumab or Sorafenib at Highest Risk of Death 2024 ·Clinical Cancer Research ·Giuseppe Cabibbo, Ciro Celsa, (unknown), Marco Enea, (unknown), (unknown), (unknown), Giulia Francesca Manfredi, Massimo Iavarone, Arndt Vogel, Amit G. Singal, María Reig, David J. Pinato, Calogero Cammà	6
6	Clinical outcomes of MAFLD versus NAFLD: A meta‐analysis of observational studies 2024 ·Liver International ·Grazia Pennisi, (unknown), Ciro Celsa, (unknown), Marco Enea, (unknown), Roberto Cannella, (unknown), Claudia La Mantia, Alessandro Mantovani, (unknown), Herbert Tilg, Giovanni Targher, (unknown), Calogero Cammà, Salvatore Petta	12
7	Turnover Intention determinants of EU hospital doctors and nurses: results from the METEOR survey 2023 ·European Journal of Public Health ·Marco Enea, Laura Maniscalco, Anke Boone, (unknown), Lode Godderis, Nico de Vries, Peter de Winter, Małgorzata Kowalska, Szymon Szemik, Domenica Matranga	2
8	Effect of pharmacological interventions and placebo on liver Histology in nonalcoholic steatohepatitis: A network meta-analysis 2022 ·Nutrition Metabolism and Cardiovascular Diseases ·Grazia Pennisi, Ciro Celsa, Marco Enea, (unknown), V. Di Marco, (unknown), (unknown), Claudia La Mantia, (unknown), Federica Vernuccio, Antonio Craxı̀, Calogero Cammà, Salvatore Petta	17
9	AGILE 3+ Score for the Diagnosis of Advanced Fibrosis and for Predicting Liver-related Events in NAFLD 2022 ·Clinical Gastroenterology and Hepatology ·Grazia Pennisi, Marco Enea, (unknown), Ciro Celsa, (unknown), (unknown), (unknown), Claudia La Mantia, (unknown), (unknown), V. Di Marco, Antonio Craxı̀, Calogero Cammà, Salvatore Petta	54
10	Longitudinal investigation of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in older patients in the province of Palermo (Southern Italy) during the early wave of the pandemic 2021 ·Archives of Medical Science ·Domenica Matranga, Laura Maniscalco, Marco Enea, (unknown), (unknown), (unknown), (unknown), Paola Di Carlo	3
11	Optimizing Sequential Systemic Therapies for Advanced Hepatocellular Carcinoma: A Decision Analysis 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, Stefania Grimaudo, Domenica Matranga, Massimo Attanasio, Paolo Bruzzi, Antonio Craxı̀, Calogero Cammà	16
12	Progression-Free Survival Early Assessment Is a Robust Surrogate Endpoint of Overall Survival in Immunotherapy Trials of Hepatocellular Carcinoma 2020 ·Cancers ·Giuseppe Cabibbo, Ciro Celsa, Marco Enea, Salvatore Battaglia, Giacomo Emanuele Maria Rizzo, (unknown), Domenica Matranga, Massimo Attanasio, María Reig, Antonio Craxı̀, Calogero Cammà	20
13	Modelling the effects of more selective trawl nets on the productivity of European hake (Merluccius merluccius) and deep-water rose shrimp (Parapenaeus longirostris) stocks in the Strait of Sicily 2018 ·Scientia Marina ·Sergio Vitale, Marco Enea, Giacomo Milisenda, Vita Gancitano, Michele Luca Geraci, Fabio Falsone, G. Bono, Fabio Fiorentino, Francesco Colloca	13
14	Survival of patients treated with sorafenib for hepatocellular carcinoma recurrence after liver transplantation: A systematic review and meta-analysis 2015 ·Digestive and Liver Disease ·Andrea Mancuso, Alessandra Mazzola, Giuseppe Cabibbo, Giovanni Perricone, Marco Enea, Antonio Galvano, Claudio Zavaglia, L Belli, Calogero Cammà	46
15	Cost-Effectiveness of Sofosbuvir-Based Triple Therapy for Untreated Patients With Genotype 1 Chronic Hepatitis C 2014 ·Hepatology ·Salvatore Petta, Giuseppe Cabibbo, Marco Enea, Fabio Salvatore Macaluso, Antonella Plaia, Raffaele Bruno, Antonio Gasbarrini, Antonio Craxı̀, Calogero Cammà	62
16	Cost-effectiveness of boceprevir or telaprevir for previously treated patients with genotype 1 chronic hepatitis C 2013 ·Journal of Hepatology ·Calogero Cammà, Salvatore Petta, Giuseppe Cabibbo, Matteo Ruggeri, Marco Enea, Raffaele Bruno, (unknown), Antonio Gasbarrini, A. Albertí, (unknown)	42
17	Cost-effectiveness of boceprevir or telaprevir for untreated patients with genotype 1 chronic hepatitis C 2012 ·Hepatology ·Calogero Cammà, Salvatore Petta, Marco Enea, Raffaele Bruno, F. Bronte, (unknown), Americo Cicchetti, Giorgio Lorenzo Colombo, V. Di Marco, Antonio Gasbarrini, Antonio Craxı̀	88
18	Peginterferon‐Α_2B plus ribavirin is more effective than peginterferon‐Α_2A plus ribavirin in menopausal women with chronic hepatitis C 2012 ·Journal of Viral Hepatitis ·Erica Villa, Calogero Cammà, Alfredo Di Leo, Aimilia Karampatou, Marco Enea, Stefano Gitto, Veronica Bernabucci, Lorena Losi, Nicola De Maria, Barbara Lei, Anna Ferrari, Ranka Vukotic, (unknown), Maria Rendina, A. Francavilla	7
19	A meta‐analysis of survival rates of untreated patients in randomized clinical trials of hepatocellular carcinoma† 2009 ·Hepatology ·Giuseppe Cabibbo, Marco Enea, Massimo Attanasio, Jordi Bruix, Antonio Craxı̀, Calogero Cammà	356
20	Meta-Analysis of the Placebo Rates of Clinical Relapse and Severe Endoscopic Recurrence in Postoperative Crohn's Disease 2008 ·Gastroenterology ·Sara Renna, Calogero Cammà, Irene Modesto, Giuseppe Cabibbo, Daniela Scimeca, (unknown), Filippo Mocciaro, Ambrogio Orlando, Marco Enea, Mario Cottone	66

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact